

ANNUAL REPORT

FY2022



LEADERSHIP MESSAGE

Dear Friends and Supporters,

For the COPD Foundation, 2022 was defined by meaningful progress, global collaboration, and a renewed commitment to improving the lives of those affected by chronic lung disease.

Our collaborative efforts have led to stronger government advocacy and improved care strategies that empower our community. Notably, we have championed global awareness and driven vital conversations about the impact of chronic lung disease on individuals and societies worldwide.

This year, we launched a six-month awareness campaign with 17 global partners, reaching nearly 800,000 people and culminating in the inaugural World Bronchiectasis Day on July 1, 2022. We continued to support critical policies for people living with COPD during our annual IMPACT Lung Health event as 31 advocates representing 21 states met virtually with their elected officials and staff.

Our mission is focused and powerful: to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. We'll do this through three strategic priorities.

1. **Advance Research Towards the Cure** with a focus on prevention, early diagnosis, and treatment to halt the progression of chronic lung disease.
2. **Improve Quality of Life** by educating, empowering, and engaging all who are impacted.
3. **Build Widespread Awareness** of chronic lung disease.

As we reflect on our achievements in 2022 and look ahead to the future, we are filled with hope and determination. Thank you for your trust, dedication, and unwavering commitment to our mission. Together, we are building a brighter future for all those affected by COPD.

Until we have a cure,



James D. Crapo, M.D.
Board Chair



MISSION

The COPD Foundation's mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.

Board of Directors

Chair:

James D. Crapo, M.D.

Vice-chair & Treasurer:

Wayne E. "Chip" Withers

Secretary:

Jean Wright, M.D., MBA

Members

Richard Casaburi, M.D., Ph.D.

Valerie Chang, J.D.

Stew Cogan, Esq.

Leonard Fromer, M.D.

Donald Gray

MeiLan K. Han, M.D., M.S.

Michael P. Meyer

Risa Stack, Ph.D.

Byron M. Thomashow, M.D.

Gerard Turino, M.D.

Robert (Bob) Wise, M.D.

Herbert Yardley

Medical and Scientific Advisory Committee

Robert (Bob) Wise, M.D.,
Chair

Jill Ohar, M.D., Vice-chair

Alvar Agusti, M.D., Ph.D.,
FRCPE

Timothy R. Aksamit, M.D.

Antonio Anzueto, M.D.

David Au, M.D., M.S.

R. Graham Barr, M.D., DrPH

Surya Bhatt, M.D.

Richard Casaburi, M.D., Ph.D.

Bartolome Celli, M.D.

James Chalmers, M.D.

James Crapo, M.D.

Gerard Criner, M.D., FACP,
FACCP

James Donohue, M.D.

Mark Dransfield, M.D.

Brad Drummond, M.D., MHS

Marilyn Foreman, M.D.

Karin Hoth, Ph.D., ABPP

Min Joo, M.D., MPH, FCCP,
ASTF

Ravi Kalhan, M.D., M.S.

Jerry Krishnan, M.D., Ph.D.

Peter Lindenauer, M.D., MSc

Barry Make, M.D.

David Mannino, M.D.

Fernando Martinez, M.D.

Mark Metersky, M.D., FCCP

Richard Mularski, M.D.,

MSHS, MCR, FCCP

Nirupama Putcha, M.D.

Stephen Rennard, M.D., RRT,
FAARC

Jean Rommes, Ph.D.

Robert A. Sandhaus, M.D.,
Ph.D.

Frank Sciurba, M.D., FCCP

Paul Simonelli, M.D., Ph.D.

Lewis J. Smith, M.D.

VISION

As the global leaders in the fight to cure COPD, bronchiectasis, and NTM lung disease, our vision is a world where everyone has the awareness, resources, and opportunity to breathe well.

Rob Stockley, M.D.

Ruth Tal-Singer, Ph.D.

Byron Thomashow, M.D.

Gerard Turino, M.D.

George Washko, M.D.

Barbara Yawn, M.D., MSc

Michael P. Meyer

Risa Stack, Ph.D.

Byron M. Thomashow, M.D.

Gerard Turino, M.D.

Robert (Bob) Wise, M.D.

Herbert Yardley

COPD360 Community Engagement Committee

Goldia Brown

Valerie Chang

Janice Cotton

Karen Erickson

Caroline Gainer

Louise Hobden

Scott Hobden

David Reynolds

Jean Rommes

John Torrence

FINANCIALS

As a 501(c)(3) organization, the COPD Foundation’s ability to advance our mission and drive meaningful impact is made possible by the generosity of our donors and corporate partners (see page 6), and funding from industry, foundations, and government grants.

- Total revenue: \$7,733,489
- Contributions & Other: \$7,411,320
- Total expenses: \$8,513,991
- Programmatic expenses: \$6,159,114

ASSETS

Cash & cash equivalents	\$1,982,080
Marketable securities	\$5,000,792
Accounts receivable	\$1,693,965
Prepaid expenses	\$527,014
Property and equipment, net	\$22,942
Marketable securities, long term	\$392,412
Total Assets	\$9,619,205

For complete information, please refer to the independently audited financial statements of the COPD Foundation at copdfoundation.org.



Dear Friends,


As we reflect on this past year, one thing stands out clearly: we could not do this without you. Your generosity, passion, and commitment to the COPD Foundation’s mission have made an extraordinary difference in the lives of millions affected by chronic lung diseases.

Because of your support, the COPD Foundation has expanded access to educational resources, advanced critical research, strengthened patient networks, and advocated for policies that put people first. Your contributions have helped individuals and families find answers, feel supported, and breathe a little easier every day.

Our community of donors continues to inspire us. Whether you gave in memory of a loved one, in celebration of progress, or simply because you believe in a better future—we are profoundly grateful.

The accomplishments of the COPD Foundation this past year are your accomplishments. We are so grateful for your kindness and your support. We look forward to what we can accomplish together in the coming years.

COPD Foundation Board of Directors and COPD Foundation Team



Thank You

COPD Foundation
Corporate Support Program Partners

- GSK, plc.
- AstraZeneca
- Insmed Incorporated
- Pfizer
- Takeda
- Sanofi-Regeneron
- Theravance
- Verona Pharma
- Viatris
- Electromed
- Pneumagen
- Wellinks
- Zambon SpA

Bronchiectasis and NTM 360 Supporters

- Anna-Maria & Stephen Kellen Foundation
- AstraZeneca
- Boehringer Ingelheim
- Electromed
- GlaxoSmithKline
- Insmed Incorporated
- NTM Info & Research
- Oregon Health and Science University
- Zambon

